Scientific article
Open access

First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy

Published inFrontiers in medicine, vol. 9, 924853
Publication date2022-05-25
First online date2022-05-25

Small cell lung cancer (SCLC) is still a lethal disease. Three phase III randomized clinical trials (IMpower133, CASPIAN, and KEYNOTE-604) have highlighted the survival gain of adding immune checkpoint inhibitors to first-line standard chemotherapy in advanced SCLC patients. In this review, we discuss the data from the three trials above. Furtherly, we analyze issues that still need to be elucidated, like the role of biomarkers, poor performance status at baseline, the presence of brain metastases, and the platinum compound's choice. Moreover, we depict the future of SCLC first-line therapy management, focusing on new therapeutic strategies currently under investigation.

  • Biomarkers
  • Chemotherapy
  • First-line therapy
  • Immunotherapy
  • Small cell lung cancer (SCLC)
Citation (ISO format)
GIUNTA, Emilio Francesco et al. First-Line Treatment for Advanced SCLC: What Is Left Behind and Beyond Chemoimmunotherapy. In: Frontiers in medicine, 2022, vol. 9, p. 924853. doi: 10.3389/fmed.2022.924853
Main files (1)
Article (Published version)
ISSN of the journal2296-858X

Technical informations

Creation01/23/2023 12:26:00 PM
First validation01/23/2023 12:26:00 PM
Update time03/16/2023 10:49:14 AM
Status update03/16/2023 10:49:13 AM
Last indexation02/01/2024 9:38:31 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack